Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tirzepatide weight reduction programme in adults with asthma and obesity
ISRCTN91904759Phase 2Not yet recruiting
- Sponsor
- University of East Anglia
- Start
- Nov 2026
- Modality
- Recombinant Proteins and Enzymes, Peptides
01
Overview
Phase 2, randomised, double-blind trial of tirzepatide in asthma and obesity (2 arms), sponsored by University of East Anglia. Primary endpoint: Asthma control at 52 weeks. Planned start Nov 2026; status: not yet recruiting.
02
Drugs
03
Conditions
asthmaobesity
Beyond the preview
Go deeper on ISRCTN91904759.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN91904759.